Totally agree with high dose NTG and BiPAP for acute pulmonary edema, but we have been dosing it a bit differently for years and it works well. We start high--200-300mcg/minute and then rapidly titrate down. We typically instruct the nurse to cut the dose in half when the BP responds, checking BPs q 5 minutes. Theoretically decreases time to effective dose and is well tolerated.
I'm part of a group of physicians for my health care system that is looking to develop an Advanced Diagnostic Pathway for Atrial Fibrillation including cardioversion. After reviewing the EMRAP episode from February 2016, I noted that Cam Berg's pathway mentions the patient's CHADS2VASC score when considering anticoagulation; however, the pathway does not take this into account when considering patients for cardioversion in the setting of Afib with RVR. Is this something that should also be taken into account when deciding the population to consider for cardioversion?
Best,
Kris
To join the conversation, you need to subscribe.
Sign up today for full access to all episodes and to join the conversation.
Lilian G. - February 25, 2016 3:22 PM
Honestly I did not like the organization of the material and that can be a bias in the learning process
Att.
Lilian J Gomes
Medical Graduate
Former Biological Sciences Graduate Student
Certified in Pedagogy
Former Research/Tx Fellow
Chandra A. - March 1, 2016 9:43 AM
Totally agree with high dose NTG and BiPAP for acute pulmonary edema, but we have been dosing it a bit differently for years and it works well. We start high--200-300mcg/minute and then rapidly titrate down. We typically instruct the nurse to cut the dose in half when the BP responds, checking BPs q 5 minutes. Theoretically decreases time to effective dose and is well tolerated.
Donald Z. - October 12, 2016 12:34 PM
Regardin Nexus ct chest rules. I suppose it is undersood that aloc makes the rule useless? For some reason that is left out. Am i missing someting?
Kristopher W. - February 13, 2019 12:07 PM
Hi,
I'm part of a group of physicians for my health care system that is looking to develop an Advanced Diagnostic Pathway for Atrial Fibrillation including cardioversion. After reviewing the EMRAP episode from February 2016, I noted that Cam Berg's pathway mentions the patient's CHADS2VASC score when considering anticoagulation; however, the pathway does not take this into account when considering patients for cardioversion in the setting of Afib with RVR. Is this something that should also be taken into account when deciding the population to consider for cardioversion?
Best,
Kris